Skip to content

Embecta Corp. EMBC Free cash flow

Free cash flow at other companies

Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$4.79M+123%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$3.58M
Mannkind logo
MannkindMNKD
-$7.25M-8.0%
Beta Bionics, Inc. Common Stock logo
Beta Bionics, Inc. Common StockBBNX
-$25.21M-24.1%
Insulet logo
InsuletPODD

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
Net income-$4.1M-117%
EPS (diluted)-$0.07-118%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp
FCF margin19.6%+16.0pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Calculated from Embecta Corp.’s reported figures.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s free cash flow?
Embecta Corp. (EMBC) reported free cash flow of $30.6M in Q1 2026.
How has Embecta Corp.'s free cash flow changed year-over-year?
Embecta Corp.'s free cash flow decreased by 3.5% year-over-year, from $31.7M to $30.6M.
What is the long-term trend for Embecta Corp.'s free cash flow?
Over 3 years (2021 to 2025), Embecta Corp.'s free cash flow has grown at a -24.2% compound annual growth rate (CAGR), from $419.5M to $182.4M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.